Tisotumab vedotin for the treatment of cervical carcinoma

被引：0
作者：
Song, Xin [1 ,2 ]
Li, Ruyi [3 ]
Wang, Hongwei [1 ]
Song, Peng [1 ]
Guo, Wenjing [4 ]
Chen, Zhe-Sheng [5 ]
机构：
[1] Gansu Univ Chinese Med, Key Lab Prevent & Treatment Chron Dis TCM Gansu P, Affiliated Hosp, 732 Jia Yuguan West Rd, Lanzhou 730000, Peoples R China
[2] Lanzhou Univ Technol, Sch Life Sci & Engn, Lanzhou, Peoples R China
[3] Zhengzhou Univ, Dept Resp & Crit Care Med, Affiliated Hosp 1, Zhengzhou, Peoples R China
[4] Gansu Univ Chinese Med, Res Ctr Tradit Chinese Med Gansu Prov, 35 Ding Xi East Rd, Lanzhou 730000, Peoples R China
[5] St Johns Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, New York, NY 11439 USA
来源：
DRUGS OF TODAY | 2022年 / 58卷 / 05期
基金：
中国国家自然科学基金;
关键词：
Tisotumab vedotin; Antibody-drug conjugates; Cervical cancer; Tissue factor; Monomethyl auristatin E; Targeted antitumor drugs; Cancer immunotherapy; Gynecological cancers; PREVIOUSLY TREATED RECURRENT; ANTIBODY-DRUG CONJUGATE; TISSUE FACTOR; CANCER; MULTICENTER; EXPRESSION; EFFICACY; SAFETY; TUMOR;
D O I：
10.1358/dot.2022.585.3400745
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Cervical cancer is one of the most common gynecological malignancies. At present, cytotoxic chemotherapeutic drugs and immunotherapy are the main therapeutic options for recurrent and metastatic cervical cancer. Tisotumab vedotin is an antibody-drug conjugate (ADC) and a potential novel treatment for cervical carcinoma. Tisotumab vedotin targets tissue factor (TF), which is highly expressed on the surface of cervical cancer cells, by delivering the cytotoxic agent monomethyl auristatin E (MMAE) directly into tumor cells. Currently, the U.S. Food and Drug Administration (FDA) has approved tisotumab vedotin for the treatment of adult female patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This article reviews the results of preclinical studies and clinical trials of tisotumab vedotin. The findings suggest that tisotumab vedotin can induce clinically significant and long-lasting remission with controllable and tolerable safety in the difficult-to-treat group of cervical cancer patients.
引用
收藏
页码：213 / 222
页数：10
相关论文
共 33 条
  • [1] [Anonymous], 2021, TIVDAK R TISOTUMAB V
  • [2] Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein
    Bogdanov, VY
    Balasubramanian, V
    Hathcock, J
    Vele, O
    Lieb, M
    Nemerson, Y
    [J]. NATURE MEDICINE, 2003, 9 (04) : 458 - 462
  • [3] Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma
    Bourbon, Estelle
    Salles, Gilles
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (10) : 1079 - 1088
  • [4] An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors
    Breij, Esther C. W.
    de Goeij, Bart E. C. G.
    Verploegen, Sandra
    Schuurhuis, Danita H.
    Amirkhosravi, Ali
    Francis, John
    Miller, Vibeke Breinholt
    Houtkamp, Mischa
    Bleeker, Wim K.
    Satijn, David
    Parren, Paul W. H. I.
    [J]. CANCER RESEARCH, 2014, 74 (04) : 1214 - 1226
  • [5] Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
    Coleman, Robert L.
    Lorusso, Domenica
    Gennigens, Christine
    Gonzalez-Martin, Antonio
    Randall, Leslie
    Cibula, David
    Lund, Bente
    Woelber, Linn
    Pignata, Sandro
    Forget, Frederic
    Redondo, Andres
    Vindelov, Signe Diness
    Chen, Menghui
    Harris, Jeffrey R.
    Smith, Margaret
    Nicacio, Leonardo Viana
    Teng, Melinda S. L.
    Laenen, Annouschka
    Rangwala, Reshma
    Manso, Luis
    Mirza, Mansoor
    Monk, Bradley J.
    Vergote, Ignace
    [J]. LANCET ONCOLOGY, 2021, 22 (05) : 609 - 619
  • [6] Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial
    de Bono, Johann S.
    Concin, Nicole
    Hong, David S.
    Thistlethwaite, Fiona C.
    Machiels, Jean-Pascal
    Arkenau, Hendrik-Tobias
    Plummer, Ruth
    Jones, Robert Hugh
    Nielsen, Dorte
    Windfeld, Kristian
    Ghatta, Srinivas
    Slomovitz, Brian M.
    Spicer, James F.
    Yachnin, Jeffrey
    Ang, Joo Ern
    Mau-Srensen, Paul Morten
    Forster, Martin David
    Collins, Dearbhaile
    Dean, Emma
    Rangwala, Reshma A.
    Lassen, Ulrik
    [J]. LANCET ONCOLOGY, 2019, 20 (03) : 383 - 393
  • [7] New developments for antibody-drug conjugate-based therapeutic approaches
    de Goeij, Bart E. C. G.
    Lambert, John M.
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2016, 40 : 14 - 23
  • [8] High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody-Drug Conjugates
    de Goeij, Bart E. C. G.
    Satijn, David
    Freitag, Claudia M.
    Wubbolts, Richard
    Bleeker, Wim K.
    Khasanov, Alisher
    Zhu, Tong
    Chen, Gary
    Miao, David
    van Berkel, Patrick H. C.
    Parren, Paul W. H. I.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2015, 14 (05) : 1130 - 1140
  • [9] Development of potent monoclonal antibody auristatin conjugates for cancer therapy
    Doronina, SO
    Toki, BE
    Torgov, MY
    Mendelsohn, BA
    Cerveny, CG
    Chace, DF
    DeBlanc, RL
    Gearing, RP
    Bovee, TD
    Siegall, CB
    Francisco, JA
    Wahl, AF
    Meyer, DL
    Senter, PD
    [J]. NATURE BIOTECHNOLOGY, 2003, 21 (07) : 778 - 784
  • [10] Cdc2-Like Kinases and DNA Topoisomerase I Regulate Alternative Splicing of Tissue Factor in Human Endothelial Cells
    Eisenreich, Andreas
    Bogdanov, Vladimir Y.
    Zakrzewicz, Andreas
    Pries, Axel
    Antoniak, Silvio
    Poller, Wolfgang
    Schultheiss, Heinz-Peter
    Rauch, Ursula
    [J]. CIRCULATION RESEARCH, 2009, 104 (05) : 589 - U59
1234